Ketorolac tromethamine transdermal gel: Development, in vitro and in vivo evaluation

Journal of Pain and Palliative Care Pharmacotherapy

Volumn 23, Issue 1, 2009, Pages 26-34

  Dubey, Rajesh ^a   Bommagani, Madhusudhan ^a   Venkateswarlu, Vobalaboina ^a   Mullangi, Ramesh ^b   Karnati, Harinder R ^b   Thammera, Ranjith K ^b   Menon, Vinu C A ^b  

^a Differentiated Products Division   (India)

^b DR REDDY'S LABORATORIES LTD   (India)

Author keywords

Dose ranging; Ketorolac tromethamine; Nociceptive; Skin penetrant; Transdermal gel

Indexed keywords

CITRIC ACID; DIMETHYL SULFOXIDE; KETOROLAC TROMETAMOL; OLEIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; SOLVENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG FORMULATION; DRUG PENETRATION; GEL; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PH; RAT; SKIN PERMEABILITY; ANIMAL; ANIMAL MODEL; BLOOD; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; EVALUATION; INTRADERMAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PAIN; SKIN ABSORPTION; WISTAR RAT;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHROMATOGRAPHY, LIQUID; CYCLOOXYGENASE INHIBITORS; DIMETHYL SULFOXIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; GELS; HYDROGEN-ION CONCENTRATION; KETOROLAC TROMETHAMINE; MALE; MODELS, ANIMAL; OLEIC ACID; PAIN; RATS; RATS, WISTAR; SKIN ABSORPTION; SOLVENTS;

EID: 67649560361     PISSN: 15360288     EISSN: 15360539     Source Type: Journal    
DOI: 10.1080/15360280902728062     Document Type: Article

References (20)

1. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Putte LBAVD, et al. Cyclooxygenase in biology and disease. FASEB J. 1998;12:1063-1073.
2. Kam PCA, See AU-L. Cyclo-oxygenase isoenzymes: physiological and pharmacological role. Anaesthesia. 2000;55:442-449.
3. Golden BD, Abramson SB. Selective cyclooxygenase-2 inhibitors. Rheum Dis Clin N Am. 1999;25:359-378.
4. Radi ZA,Khan NK. Effects of cyclooxygenase inhibition on the gastrointestinal tract. Exp Toxicol Pathol. 2006;58:163-173.
5. Fennerty MB. NSAID-related gastrointestinal injury: evidence-based approach to a preventable complication. Postgrad Med. 2001;110:163-173.
6. Whittle BJR. Cyclooxygenase and nitric oxide systems in the gut as therapeutic targets for safer antiinflammatory drugs.CurrOpin Pharmacol. 2004;4:538-545.
7. Whittle BJR. Mechanisms underlying intestinal injury induced by anti-inflammatory COX inhibitors. Eur J Pharmacol. 2004;500:427-439.
8. Alsarra IA, Bosela AA, Ahmed SM, Mahrous GM. Proniosomes as a drug carrier for transdermal delivery of ketorolac. Eur J Pharmaceut Biopharmaceut. 2005;59:485-490.
9. Mishra A, Veerasamy R, Jain PK, Dixit VK, Agrawal RK. Synthesis, characterization and pharmacological evaluation of amide prodrugs of ketorolac. Eur J Med Chem. 2008;43:2464-2472.
10. Puglia C, Filosa R, Peduto A, Caprariis PD, Rizza L, Bonina F, et al. Evaluation of alternative strategies to optimize ketorolac transdermal delivery. AAPS Pharm-SciTech. 2006;7:Article 64.
11. Tiwari SB, Udupa N. Investigation into the potential of iontophoresis facilitated delivery of ketorolac. Int J Pharmaceut. 2003;260:93-103.
12. Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev. 2004;56:603-618.
13. Gorukanti SR, Li L, Kim KH. Transdermal delivery of antiparkinsonian agent, benztropine. I. Effect of vehicles on skin permeation. Int J Pharmaceut. 1999;192:159-172.
14. Liu H, Li S, Wang Y, Yao H, Zhang Y. Effect of vehicles and enhancers on the topical delivery of cyclosporin A. Int J Pharmaceut. 2006;311:182-186.
15. Gwak HS, Chun IK. Effect of vehicles and penetration enhancers on the in vitro percutaneous absorption of tenoxicam through hairless mouse skin. Int J Pharmaceut. 2002;236:57-64.
16. Panigrahi L, Pattnaik S, Ghosal SK. The effect of pH and organic ester penetration enhancers on skin permeation kinetics of terbutaline sulfate from pseudolatextype transdermal delivery systems through mouse and human cadaver skins. AAPS PharmSciTech. 2005;6:Article 25.
17. Mitragotri S. Modeling skin permeability to hydrophilic and hydrophobic solutes based on four permeation pathways. J Controlled Release. 2003;86:69-92.
18. Moser K, Kriwet K, Kalia YN, Guy RH. Enhanced skin permeation of a lipophilic drug using supersaturated formulations. J Controlled Release. 2001;73:245-253. (Pubitemid 32539253)
19. El Maghrabya GMM, Campbell M, Finnin BC. Mechanisms of action of novel skin penetration enhancers: Phospholipid versus skin lipid liposomes. International Journal of Pharmaceutics . 2005;305:90-104.
20. Refai H, Müller-Goymann CC. The influence of dilution of topical semisolid preparations on hydrocortisone permeation through excised human stratum corneum. European Journal of Pharmaceutics and Biopharmaceutics . 2002;54:143-150.